Patents by Inventor Penglie Zhang

Penglie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA
    Publication number: 20120083602
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: September 28, 2011
    Publication date: April 5, 2012
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES
    Publication number: 20120010214
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: May 9, 2011
    Publication date: January 12, 2012
    Applicant: ChemoCentryx, Inc.
    Inventors: Lianfa Li, Andrew M.K. Pennell, Penglie Zhang
  • Benzamides and related inhibitors of factor Xa
    Patent number: 8063036
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: November 22, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
    Patent number: 7960388
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: June 14, 2011
    Assignee: ChemoCentryx, Inc.
    Inventors: Lianfa Li, Andrew M.K. Pennell, Penglie Zhang
  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20110098308
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: July 1, 2010
    Publication date: April 28, 2011
    Applicant: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • MODULATORS OF CXCR7
    Publication number: 20110014121
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 29, 2010
    Publication date: January 20, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
  • N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES
    Publication number: 20100331302
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 8, 2010
    Publication date: December 30, 2010
    Applicant: Chemocentryx, Inc.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • MODULATORS OF CXCR7
    Publication number: 20100311712
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 12, 2010
    Publication date: December 9, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Mark M. GLEASON, Juan C. JAEN, Lianfa LI, Jeffrey P. MCMAHON, Jay POWERS, Yibin ZENG, Penglie ZHANG, Junfa FAN
  • BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA
    Publication number: 20100298284
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: April 7, 2010
    Publication date: November 25, 2010
    Inventors: Bing-Yan ZHU, Penglie ZHANG, Lingyan WANG, Wenrong HUANG, Erick A. GOLDMAN, Wenhao LI, Jingmei ZUCKETT, Yonghong SONG, Robert M. SCARBOROUGH
  • SUBSTITUTED PIPERAZINES
    Publication number: 20100240618
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: September 8, 2009
    Publication date: September 23, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew M.K. Pennell, James B. Aggen, J.J. Kim Wright, Subhabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi, Wei Chen, Penglie Zhang
  • Monocyclic and bicyclic compounds and methods of use
    Patent number: 7790726
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: September 7, 2010
    Assignee: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Lianfa Li, Edward J. Sullivan, Wei Chen, Kevin Lloyd Greenman
  • OXO-imidazolidines as modulators of chemokine receptors
    Patent number: 7786157
    Abstract: The present invention provides compounds having formula (I): or pharmaceutically acceptable salts and N-oxides thereof, wherein the subscript m is an integer from 0-4; Ar is an optionally substituted aryl; B is an optionally substituted aryl; L1 is an optionally substituted linking group selected from the group consisting of C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and —CH2N(Ru)X5—; and L2 is a bond or C1-3 alkylene. The compounds act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: August 31, 2010
    Assignee: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, Lianfa Li, Edward J. Sullivan
  • N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
    Patent number: 7776877
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 17, 2010
    Assignee: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M. K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • Azaindazole compounds and methods of use
    Patent number: 7777035
    Abstract: Methods are provided for the synthesis of 1-[4-(substituted phenyl)-piperazin-1-yl ] -2- [3-(1H-imidazol-2-yl)-pyrazolo [3,4-b]pyridin-1-yl]-ethanone compounds via construction of the imidazole portion onto the corresponding aldehyde or nitrile compounds.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: August 17, 2010
    Assignee: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES
    Publication number: 20100173911
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: November 12, 2009
    Publication date: July 8, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Lianfa Li, Andrew M.K. Pennell, Penglie Zhang
  • MODULATORS OF CXCR7
    Publication number: 20100150831
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: November 4, 2009
    Publication date: June 17, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
  • Benzamides and related inhibitors of factor Xa
    Patent number: 7727981
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: June 1, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • Benzamides and related inhibitors of factor Xa
    Patent number: 7727982
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compound and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: June 1, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS
    Publication number: 20100113472
    Abstract: Methods are provided for the treatment of osteoporosis and multiple myeloma, using 3-imidazoyl-pyrazolo[3,4-b]pyridine compounds.
    Type: Application
    Filed: November 3, 2009
    Publication date: May 6, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Daniel Dairaghi, Lianfa Li, Andrew M.K. Pennell, Penglie Zhang
  • 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES
    Publication number: 20100069396
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 18, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Yibin Zeng